Skip Over Navigation Links

Research

TRND Application Scoring Matrix

 Score 1-3
High Score
Score 4-6
Average Score
Score 7-9
Poor Score
Target and Therapeutic Validation (30%)Target has been validated in both animal pharmacology studies as well as in humans and there is a link to therapeutic indication.Target has been validated primarily in animal pharmacology or knock out mouse studies.Target has been validated in primarily in vitro in animals and/or humans.
Strength of Current Data Package (30%)

High quality in the relevant areas:

  • Medicinal Chemistry
  • ADME
  • PK/PD
  • Toxicology
  • In vivo models
  • Secondary and tertiary assays
  • Formulation
  • Chemical Manufacturing and Controls (CMC) - small molecules
  • Expression/Purification - Biologics

High quality in some of the relevant areas and medium quality in other relevant areas:

  • Medicinal Chemistry
  • ADME
  • PK/PD
  • Toxicology
  • In vivo models
  • Secondary and tertiary assays
  • Formulation
  • Chemical Manufacturing and Controls (CMC) - small molecules
  • Expression/Purification - Biologics

Medium or marginal quality in the relevant areas

  • Medicinal Chemistry
  • ADME
  • PK/PD
  • Toxicology
  • In vivo models
  • Secondary and tertiary assays
  • Formulation
  • Chemical Manufacturing and Controls (CMC) - small molecules
  • Expression/Purification - Biologics
Feasibility to Reach First in Human (20%)

Have most of the following:

  • Animal models to establish efficacy
  • Clinical translation, establish clinical endpoints
  • Patient population well defined with registries
  • Biobanks
  • Natural history studies complete
  • Market opportunity analysis

Have many of the following:

  • Animal models to establish efficacy
  • Clinical translation, establish clinical endpoints
  • Patient population well defined with registries
  • Biobanks
  • Natural history studies complete
  • Market opportunity analysis

Have few to none of the following:

  • Animal models to establish efficacy
  • Clinical translation, establish clinical endpoints
  • Patient population well defined with registries
  • Biobanks
  • Natural history studies complete
  • Market opportunity analysis
Medical Impact Relative to Current Standard of Care (10%)There is no current treatment for the disease or clinical outcome. 

Or the current standard of care has considerable disadvantages or very limited utility
The current standard of care has potential disadvantages (resistance).

Or the current standard of care somewhat limited utility
The current standard of care is adequate, but additional treatments are desired.
Likelihood of External Adoption (10%)Will themselves or has a committed partner that will take this compound to registrationCompounds of this nature have been adopted by partners and taken to registration

Or a partner has expressed interest
No interest has been noted for the compound or the disease

Related Links